

# Thierry Lefevre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9224314/publications.pdf>

Version: 2024-02-01

89

papers

6,821

citations

94433

37

h-index

62596

80

g-index

98

all docs

98

docs citations

98

times ranked

6420

citing authors

#	ARTICLE	IF	CITATIONS
1	Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. New England Journal of Medicine, 2018, 379, 2297-2306.	27.0	1,276
2	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. JAMA - Journal of the American Medical Association, 2014, 312, 162.	7.4	762
3	Frailty in Older Adults Undergoing Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 70, 689-700.	2.8	561
4	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation, 2019, 140, 420-433.	1.6	263
5	Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses. Circulation: Cardiovascular Interventions, 2019, 12, e008434.	3.9	234
6	Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. EuroIntervention, 2018, 13, 1540-1553.	3.2	185
7	Sex-Related Differences in Clinical Presentation and Outcome of Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. Journal of the American College of Cardiology, 2012, 59, 566-571.	2.8	179
8	Impact of Post-Procedural Aortic Regurgitation on Mortality After Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2012, 5, 1247-1256.	2.9	150
9	Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. European Journal of Heart Failure, 2019, 21, 1619-1627.	7.1	149
10	Bicuspid Aortic Valve Anatomy and Relationship With Devices: The BAVARD Multicenter Registry. Circulation: Cardiovascular Interventions, 2019, 12, e007107.	3.9	125
11	Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement. Circulation, 2020, 141, 243-259.	1.6	118
12	Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses. JACC: Cardiovascular Interventions, 2017, 10, 1048-1056.	2.9	117
13	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2860-2868.	2.8	116
14	Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. American Heart Journal, 2018, 200, 44-50.	2.7	111
15	Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients. Journal of the American College of Cardiology, 2016, 68, 1637-1647.	2.8	109
16	Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients. Circulation, 2018, 138, 2597-2607.	1.6	109
17	Temporal Trends in Chronic Total Occlusion Interventions in Europe. Circulation: Cardiovascular Interventions, 2018, 11, e006229.	3.9	105
18	Transcatheter Replacement of Failed Bioprosthetic Valves. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	104

#	ARTICLE	IF	CITATIONS
19	Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry. JACC: Cardiovascular Interventions, 2019, 12, 335-342.	2.9	99
20	Percutaneous coronary intervention for obstructive bifurcation lesions: the 14th consensus document from the European Bifurcation Club. EuroIntervention, 2019, 15, 90-98.	3.2	99
21	Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. EuroIntervention, 2018, 14, 112-120.	3.2	94
22	Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). European Heart Journal, 2018, 39, 676-684.	2.2	91
23	Chimney Stenting for Coronary Occlusion During TAVR. JACC: Cardiovascular Interventions, 2020, 13, 751-761.	2.9	90
24	Acute and 30-Day Outcomes in Women After TAVR. JACC: Cardiovascular Interventions, 2016, 9, 1589-1600.	2.9	85
25	Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use. Journal of the American College of Cardiology, 2019, 73, 13-21.	2.8	85
26	Malnutrition and Mortality in Frail and Non-Frail Older Adults Undergoing Aortic Valve Replacement. Circulation, 2018, 138, 2202-2211.	1.6	79
27	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1-12.	2.9	77
28	Femoral Versus Nonfemoral Peripheral Access for Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2728-2739.	2.8	75
29	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With Durable Polymer Everolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2018, 11, 995-1002.	2.9	63
30	Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club. EuroIntervention, 2018, 14, e467-e474.	3.2	60
31	European Bifurcation Club white paper on stenting techniques for patients with bifurcated coronary artery lesions. Catheterization and Cardiovascular Interventions, 2020, 96, 1067-1079.	1.7	57
32	Joint consensus on the use of OCT in coronary bifurcation lesions by the European and Japanese bifurcation clubs. EuroIntervention, 2019, 14, e1568-e1577.	3.2	51
33	Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. American Journal of Cardiology, 2018, 122, 1028-1035.	1.6	47
34	The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS) Tj ETQq0 0 0 regBT /Overlock 10 Tf	1.7	46
35	Left Ventricular Rapid Pacing Via the Valve Delivery Guidewire in Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 2449-2459.	2.9	46
36	Assessment of Long-Term Structural Deterioration of Transcatheter Aortic Bioprosthetic Valves Using the New European Definition. Circulation: Cardiovascular Interventions, 2019, 12, e007597.	3.9	46

#	ARTICLE	IF	CITATIONS
37	Impact of Direct Transcatheter Aortic Valve Replacement Without Balloon Aortic Valvuloplasty on Procedural and Clinical Outcomes. JACC: Cardiovascular Interventions, 2018, 11, 1956-1965.	2.9	42
38	Sex-Specific Determinants of Outcomes After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005363.	2.2	36
39	Frailty and Bleeding in Older Adults Undergoing TAVR or SAVR. JACC: Cardiovascular Interventions, 2020, 13, 1058-1068.	2.9	36
40	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 1374-1381.	1.7	35
41	Development of a Risk Score Based on Aortic Calcification to Predict 1-Year Mortality After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Imaging, 2019, 12, 123-132.	5.3	32
42	Vibrational Circular Dichroism Reveals Supramolecular Chirality Inversion of $\pm$ -Synuclein Peptide Assemblies upon Interactions with Anionic Membranes. ACS Nano, 2019, 13, 3232-3242.	14.6	30
43	Habitual Physical Activity in Older Adults Undergoing TAVR. JACC: Cardiovascular Interventions, 2019, 12, 781-789.	2.9	29
44	Incidence and predictors of coronary obstruction following transcatheter aortic valve implantation in the real world. Catheterization and Cardiovascular Interventions, 2017, 90, 1192-1197.	1.7	28
45	Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club. EuroIntervention, 2018, 13, e1794-e1803.	3.2	28
46	Transcatheter Aortic Valve Replacement in the Catheterization Laboratory Versus Hybrid Operating Room. JACC: Cardiovascular Interventions, 2018, 11, 2195-2203.	2.9	27
47	Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. Journal of Cardiovascular Computed Tomography, 2018, 12, 338-343.	1.3	25
48	Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. Journal of Thrombosis and Thrombolysis, 2013, 35, 483-493.	2.1	24
49	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 1124-1131.	1.7	22
50	Carotid versus femoral access for transcatheter aortic valve implantation: a propensity score inverse probability weighting study. European Journal of Cardio-thoracic Surgery, 2019, 56, 1140-1146.	1.4	21
51	Prognostic value of aortic root calcification volume on clinical outcomes after transcatheter balloon-expandable aortic valve implantation. Catheterization and Cardiovascular Interventions, 2015, 86, 1105-1113.	1.7	19
52	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). American Journal of Cardiology, 2019, 123, 1494-1500.	1.6	19
53	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. American Journal of Cardiology, 2017, 120, 2025-2030.	1.6	18
54	Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: Insights from the FRANCE-2 registry. Clinical Cardiology, 2017, 40, 1316-1322.	1.8	18

#	ARTICLE	IF	CITATIONS
55	Implementation of the transradial approach as an alternative vascular access for transcatheter aortic valve replacement guidance: Experience from a high-volume center. Catheterization and Cardiovascular Interventions, 2019, 93, 1367-1373.	1.7	18
56	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2018, 122, 1909-1916.	1.6	18
57	Analysis of length of stay after transfemoral transcatheter aortic valve replacement: results from the FRANCE TAVI registry. Clinical Research in Cardiology, 2021, 110, 40-49.	3.3	18
58	Prognostic Impact of Pre-Transcatheter and Post-Transcatheter Aortic Valve Intervention Troponin: A Large Cohort Study. Journal of the American Heart Association, 2019, 8, e011111.	3.7	17
59	Interaction Between Frailty and Access Site in Older Adults Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 2185-2192.	2.9	16
60	TAVI: Simplification Is the Ultimate Sophistication. Frontiers in Cardiovascular Medicine, 2018, 5, 96.	2.4	16
61	Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II and BIOFLOW II trials. International Journal of Cardiology, 2020, 300, 60-65.	1.7	13
62	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's International Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. Catheterization and Cardiovascular Interventions, 2020, 96, 198-207.	1.7	13
63	Hemodynamic Performances and Clinical Outcomes in Patients Undergoing Valve-in-Valve Versus Native Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2019, 124, 90-97.	1.6	11
64	One-Year Outcomes of a European Transcatheter Aortic Valve Implantation Cohort According to Surgical Risk. Circulation: Cardiovascular Interventions, 2019, 12, e006724.	3.9	11
65	Is sex associated with adverse outcomes after percutaneous coronary intervention for CTO?. International Journal of Cardiology, 2019, 288, 29-33.	1.7	10
66	Coronary Artery Fenestration. JACC: Cardiovascular Interventions, 2018, 11, 1905-1907.	2.9	9
67	Significance of the CAPRI risk score to predict heart failure hospitalization post-TAVI: The CAPRI-HF study. International Journal of Cardiology, 2019, 296, 98-102.	1.7	9
68	Outcomes of transcatheter aortic valve replacement without predilation of the aortic valve: Insights from 1544 patients included in the SOURCE 3 registry. International Journal of Cardiology, 2019, 296, 32-37.	1.7	9
69	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2020, 125, 441-448.	1.6	9
70	Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1027-1037.	1.7	8
71	Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. Canadian Journal of Cardiology, 2019, 35, 199-207.	1.7	7
72	Evaluation of length of stay after transfemoral transcatheter aortic valve implantation with SAPIEN 3 prosthesis: A French multicentre prospective observational trial. Archives of Cardiovascular Diseases, 2020, 113, 391-400.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheterization and Cardiovascular Interventions, 2021, 98, E908-E917.	1.7	7
74	Safety and effectiveness of a transaortic approach for TAVI: procedural and midterm outcomes of 265 consecutive patients in a single centre. Interactive Cardiovascular and Thoracic Surgery, 2020, 30, 400-407.	1.1	5
75	Characteristics of stent thrombosis in bifurcation lesions analysed by optical coherence tomography. EuroIntervention, 2018, 13, 2174-2181.	3.2	5
76	Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1016-1026.	1.7	4
77	Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry. Archives of Cardiovascular Diseases, 2019, 112, 113-123.	1.6	4
78	General Anesthesia or Conscious Sedation for Transfemoral Aortic Valve Replacement with the SAPIEN 3 Transcatheter Heart Valve. International Heart Journal, 2020, 61, 713-719.	1.0	4
79	TCT-14 Final 5-Year Outcomes of the REPRISE II Study: Long-term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve. Journal of the American College of Cardiology, 2018, 72, B6.	2.8	2
80	Seudoaneurisma ventricular derecho tras implante valve-in-valve tricuspídeo. Revista Espanola De Cardiologia, 2018, 71, 1070.	1.2	2
81	Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study. EuroIntervention, 2020, 16, 654-662.	3.2	2
82	«Todo debe hacerse tan simple como sea posible, pero no más simple». Revista Espanola De Cardiologia, 2018, 71, 418-419.	1.2	1
83	«Everything Should be Made as Simple as Possible but Not Simpler». Revista Espanola De Cardiologia (English Ed ), 2018, 71, 418-419.	0.6	1
84	Double Anomalous Aortic Origin of a Coronary Artery With Intramural Course. JACC: Cardiovascular Interventions, 2018, 11, e153-e155.	2.9	1
85	Role for Vascular Factors in Long-Term Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 125, 1884-1889.	1.6	1
86	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. Catheterization and Cardiovascular Interventions, 2020, 96, E688-E694.	1.7	1
87	EuroCTO Club 2018 meeting: «Experts Live» in Toulouse. EuroIntervention, 2019, 14, e1814-e1817.	3.2	1
88	Right Ventricular Pseudoaneurysm After Percutaneous Tricuspid Valve-in-valve Implantation. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 1070.	0.6	0
89	TCT-276 Individual Patient Data Analysis of the BIOFLOW Study Program Comparing Safety and Efficacy of a Bioresorbable Polymer Sirolimus-Eluting Stent to a Durable Polymer Everolimus-Eluting Stent. Journal of the American College of Cardiology, 2019, 74, B275.	2.8	0